On the second day too, the panel discussion on the trends and opportunities regarding the oral solid dosage forms saw Dr Vinod Arora, Principal Advisor, Institute of Good Manufacturing Practices India (IGMPI) as the moderator of the session. The other panellists included Dr Kavita Inamdar, CTO, Indoco Remedies; Dr Krishnakanth Gandhi, MD, Solinova Life Sciences and Ravi Kochhar, Head, R&D, Beximco Pharmaceuticals, Bangladesh. The panellists began the discussion by deliberating on various dosage forms like mini tabs, micro tabs, etc. One of the panelists, Kochar, said that such tablets are the way forward. Further, moving along patient-centric dosage forms and ease of dosing, this trend will go on and one has to build upon it, he stressed.
Going forward, the panelists discussed about the fixed-dose combinations and their clinical as well as business advantages, along with the role of continuous manufacturing in the Indian pharma industry. Dr Gandhi highlighted that continuous manufacturing is not new in the industry. Before the pharmaceuticals, oil refineries, chemicals, synthetic fibres, fertilisers, power generation, natural gas and waste water management are the various areas where continuous manufacturing concept is being used, he informed. He also said that there are three major factors driving continuous manufacturing – initial investment set up, regulation and technology. Thus, it is the right time to focus on it.
In addition to it, the panelists also shared their views on digital medicine. Dr Inamdar, in this reg